All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $201M | $-11M | $-19M | $-9M | -10.6% | 20.2% | -38.8% |
| 2024 | $167M | $-23M | $-31M | $-23M | -18.5% | 20.4% | -28.7% |
| 2023 | $139M | $-34M | $-43M | $-27M | -25.6% | 30.5% | -29.3% |
| 2022 | $106M | $-55M | $-61M | $-51M | -62.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 200.92 |
| Operating Revenue | 200.92 |
| Cost Of Revenue | 41.05 |
| Gross Profit | 159.88 |
| Operating Expense | 182.21 |
| Research And Development | 17.45 |
| Selling General And Administration | 164.76 |
| Total Expenses | 223.26 |
| Operating Income | -22.33 |
| Total Operating Income As Reported | -22.33 |
| EBITDA | -10.51 |
| Normalized EBITDA | -10.51 |
| EBIT | -16.28 |
| Interest Income | 6.07 |
| Interest Expense | 2.63 |
| Net Interest Income | 3.45 |
| Other Non Operating Income Expenses | -0.02 |
| Other Income Expense | -0.02 |
| Interest Income Non Operating | 6.07 |
| Interest Expense Non Operating | 2.63 |
| Net Non Operating Interest Income Expense | 3.45 |
| Pretax Income | -18.90 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -18.90 |
| Net Income From Continuing And Discontinued Operation | -18.90 |
| Net Income From Continuing Operation Net Minority Interest | -18.90 |
| Net Income | -18.90 |
| Net Income Common Stockholders | -18.90 |
| Net Income Including Noncontrolling Interests | -18.90 |
| Normalized Income | -18.90 |
| Diluted NI Availto Com Stockholders | -18.90 |
| Basic Average Shares | 42.96 |
| Diluted Average Shares | 42.96 |
| Reconciled Depreciation | 5.77 |
| Reconciled Cost Of Revenue | 41.05 |
| General And Administrative Expense | 40.54 |
| Other Gand A | 40.54 |
| Selling And Marketing Expense | 124.22 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| SI-BONE, Inc.this co. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Zevra Therapeutics, Inc. | ZVRA | $660M | 7.93 |
| - |
| - |
| - |
| - |
| 4.27 |
| 53.8% |
| 6.70 |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Peer Median | - | -6.75 | 3.72 | -37.3% | -2.95 | |